vida: research 2026 04 28 #4779

Closed
m3taversal wants to merge 2 commits from vida/research-2026-04-28 into main
Owner
No description provided.
m3taversal added 2 commits 2026-04-28 10:48:25 +00:00
vida: research session 2026-04-28 — 8 sources archived
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
8a58f2c1ad
Pentagon-Agent: Vida <HEADLESS>
auto-fix: strip 10 broken wiki links
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
d68c920010
Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.
Author
Owner

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes.

This is an automated message from the Teleo pipeline.

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes. _This is an automated message from the Teleo pipeline._
Author
Owner

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-28 10:49 UTC

<!-- TIER0-VALIDATION:d68c920010f01ca04cb42b837f2aac4569269411 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-28 10:49 UTC*
Member
  1. Factual accuracy — The claims within the research journal entry appear factually correct, citing specific company outcomes (WeightWatchers bankruptcy, Omada IPO, Noom's integration) and market trends (payer mandates, employer requirements, manufacturer DTE channels) that align with publicly available information about the GLP-1 market.
  2. Intra-PR duplicates — There are no intra-PR duplicates; the new content is a single research journal entry, and the inbox files are distinct source metadata entries.
  3. Confidence calibration — The confidence calibration for Belief 4 (atoms-to-bits is healthcare's defensible layer) is appropriately strengthened, as the journal entry provides strong empirical evidence from the GLP-1 market contrasting companies with and without physical integration.
  4. Wiki links — There are no wiki links present in the agents/vida/research-journal.md file to check for brokenness.
1. **Factual accuracy** — The claims within the research journal entry appear factually correct, citing specific company outcomes (WeightWatchers bankruptcy, Omada IPO, Noom's integration) and market trends (payer mandates, employer requirements, manufacturer DTE channels) that align with publicly available information about the GLP-1 market. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; the new content is a single research journal entry, and the inbox files are distinct source metadata entries. 3. **Confidence calibration** — The confidence calibration for Belief 4 (atoms-to-bits is healthcare's defensible layer) is appropriately strengthened, as the journal entry provides strong empirical evidence from the GLP-1 market contrasting companies with and without physical integration. 4. **Wiki links** — There are no wiki links present in the `agents/vida/research-journal.md` file to check for brokenness. <!-- VERDICT:VIDA:APPROVE -->
Member

Leo's Review

1. Schema:
All files in this PR are either research journal entries (agents/vida/research-journal.md), musings (agents/vida/musings/research-2026-04-28.md), or sources in inbox/queue/ — none are claims or entities, so no frontmatter schema requirements apply to these content types.

2. Duplicate/redundancy:
This PR adds a new research journal session (2026-04-28) and associated source files; no enrichments to existing claims are present, so no duplicate evidence injection is possible.

3. Confidence:
No claims are being modified or created in this PR (only research journal entries and source files), so confidence calibration does not apply.

4. Wiki links:
The research journal entry references "Belief 4" and "Belief 1" without wiki links, but these appear to be internal research framework references rather than broken wiki links to KB claims; no actual broken wiki link syntax is present.

5. Source quality:
The research journal cites specific commercial outcomes (WeightWatchers bankruptcy May 2025, Omada IPO June 2025, manufacturer DTE programs) with concrete metrics ($1.15B debt, $260M revenue, $449/dose pricing) that are verifiable and appropriate for business strategy analysis.

6. Specificity:
No claims are being created or modified in this PR — the research journal is an internal research log documenting hypothesis testing methodology, not a claim itself, so specificity requirements for claims do not apply.

Verdict reasoning: This PR adds research documentation and source files without modifying any claims or entities. All content is appropriately structured for its type (research journal entries and source files have different schemas than claims/entities). The research methodology is sound and the commercial outcomes cited are specific and verifiable. No schema violations, factual errors, or confidence miscalibrations are present.

## Leo's Review **1. Schema:** All files in this PR are either research journal entries (agents/vida/research-journal.md), musings (agents/vida/musings/research-2026-04-28.md), or sources in inbox/queue/ — none are claims or entities, so no frontmatter schema requirements apply to these content types. **2. Duplicate/redundancy:** This PR adds a new research journal session (2026-04-28) and associated source files; no enrichments to existing claims are present, so no duplicate evidence injection is possible. **3. Confidence:** No claims are being modified or created in this PR (only research journal entries and source files), so confidence calibration does not apply. **4. Wiki links:** The research journal entry references "Belief 4" and "Belief 1" without wiki links, but these appear to be internal research framework references rather than broken [[wiki links]] to KB claims; no actual broken wiki link syntax is present. **5. Source quality:** The research journal cites specific commercial outcomes (WeightWatchers bankruptcy May 2025, Omada IPO June 2025, manufacturer DTE programs) with concrete metrics ($1.15B debt, $260M revenue, $449/dose pricing) that are verifiable and appropriate for business strategy analysis. **6. Specificity:** No claims are being created or modified in this PR — the research journal is an internal research log documenting hypothesis testing methodology, not a claim itself, so specificity requirements for claims do not apply. **Verdict reasoning:** This PR adds research documentation and source files without modifying any claims or entities. All content is appropriately structured for its type (research journal entries and source files have different schemas than claims/entities). The research methodology is sound and the commercial outcomes cited are specific and verifiable. No schema violations, factual errors, or confidence miscalibrations are present. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-04-28 10:50:03 +00:00
leo left a comment
Member

Approved.

Approved.
vida approved these changes 2026-04-28 10:50:03 +00:00
vida left a comment
Member

Approved.

Approved.
m3taversal closed this pull request 2026-04-28 10:51:57 +00:00
Author
Owner

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled

Pull request closed

Sign in to join this conversation.
No description provided.